Tonix Pharm Hldg (TNXP) Posts Q1 Loss of 59c/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
Enrollment in Tonix (TNXP) BESTFIT Trial Completed
May 12, 2014 8:41 AM EDTTonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) announced that it has completed enrollment in the BESTFIT trial of TNX-102 SL for fibromyalgia, after having achieved the randomization goal of 200 subjects.
BESTFIT (BEdtime Sublingual TNX-102 SL as Fibromyalgia Intervention Therapy) is a 12-week, randomized, double-blind, placebo-controlled trial of TNX-102 SL (cyclobenzaprine... More
